Rituximab in a B cell-driven regimen for the treatment of recurrent membranoproliferative glomerulonephritis after kidney transplantation

Int Urol Nephrol. 2014 Oct;46(10):2053-4. doi: 10.1007/s11255-014-0792-0. Epub 2014 Jul 31.

Authors

Igor Denizarde Bacelar Marques¹, Janaina Ramalho, Daísa Ribeiro David, William Carlos Nahas, Elias David-Neto

Affiliation

¹ Renal Transplant Service, Hospital das Clínicas, Instituto Central, University of São Paulo School of Medicine, sala 7036, Av. Dr. Enéas de Carvalho Aguiar 255, São Paulo, SP, 05403-000, Brazil, [email protected].

PMID: 25080208
DOI: 10.1007/s11255-014-0792-0

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Murine-Derived / therapeutic use*
B-Lymphocytes / immunology
Biomarkers / urine
Biopsy
Female
Glomerulonephritis, Membranoproliferative / immunology
Glomerulonephritis, Membranoproliferative / therapy*
Humans
Immunologic Factors / therapeutic use*
Kidney Transplantation*
Middle Aged
Plasmapheresis
Rituximab

Substances

Antibodies, Monoclonal, Murine-Derived
Biomarkers
Immunologic Factors
Rituximab